Frequently Asked Questions

We create and co-create device, diagnostic, digital, tech-enabled services and health tech companies across heart and brain health, and related conditions (e.g., autoimmune, kidney, metabolic, etc.). Studio Red does not take on therapeutics or drug development.

Typically, Studio Red does not engage in therapeutics or drug development projects.

Very rarely, if there are complementary resources that the American Heart Association can bring to the project and we believe there is a reasonable way to engage through our Studio, we will consider it.

Studio Red earmarks up to $1 million in cash and in-kind support per project. We combine direct investment and operational support to accelerate development. As each project evolves into a standalone company, we work closely with leadership to secure additional external funding.

Studio Red does not take on projects without a direct or indirect connection to heart and brain health or to the mission of the American Heart Association. We typically do not develop biotech companies. We do not make venture investments in companies that are not developed or co-developed in association with the Studio.

There is no set timeline. On average, projects spend 12 to 18 months in the Studio. Our ultimate goal is to spin out each company as an independent enterprise as quickly as is practical and sustainable.

We expect a reasonable equity ownership commensurate with our contribution of resources, direct investment and “sweat equity.” Each company creation project is designed to align the interests of all involved.

Yes. Studio Red incubates, creates and co-creates companies across the health care spectrum and is part of American Heart Association Ventures. In contrast, CHTI is a health tech convening organization that leads the Innovator’s Network, which licenses select Heart Association assets to health tech companies. CHTI does not make venture investments or engage in company creation.